By Arlene Weintraub
The U.K. government's two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses from six companies. J&J and Novavax will expand their clinical trials in the U.K., too, as the government pledges to get the vaccines on the market by mid-2021 if they succeed.
read more
By Heather Landi
The COVID-19 pandemic has had unpredictable impacts on the healthcare industry. What many industry stakeholders had not counted on was the rapid adoption of artificial intelligence during the health crisis. During a Fierce AI week virtual panel, executives from Google Cloud, Suki and Olive spell out what's driving the demand for AI and what's next for healthcare innovation.
read more
By Conor Hale
The kits can connect 20 standard hospital beds to a central patient monitoring station and be up and running in an average of five hours.
read more
By Eric Sagonowsky
Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, Johnson & Johnson is moving forward with negotiations on a deal twice that size with the European Union. In details unveiled Thursday, J&J is in talks to supply the EU with 200 million doses of its coronavirus vaccine candidate—if the program succeeds in testing.
read more
By Robert King
Experts say that AI and machine learning could help insurers navigate future surges of healthcare costs that could arise due to the pandemic.
read more
By Amirah Al Idrus
On the heels of a $640 million private round, Germany’s CureVac has netted $213 million in its Nasdaq debut. The bulk of the proceeds will bankroll its mRNA vaccine for COVID-19, with the rest going to manufacturing, platform development and other programs. The company also picked up another $118 million through a private placement to longtime investor, Dietmar Hopp.
read more
By Nick Paul Taylor
Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus.
read more
By Tina Reed
Machines are beginning to outshine their human counterparts as AI is applied to an increasing number of healthcare tasks, experts said during a recent Fierce AI event.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
The EU tapped AstraZeneca for advance purchase of 300 million shots. J&J is in talks to deploy 200 million vaccines to the EU and inked a deal with the U.K. for 30 million. Sinopharm unveiled phase 2 data on its vaccine. The U.S. is looking to supply COVID-19 shots with zero copay. And the FDA rejected Henry Ford Health System's bid for hydroxychloroquine use.
read more
